EA200801735A1 - Антиамилоидные иммуногенные композиции, способы и применения - Google Patents

Антиамилоидные иммуногенные композиции, способы и применения

Info

Publication number
EA200801735A1
EA200801735A1 EA200801735A EA200801735A EA200801735A1 EA 200801735 A1 EA200801735 A1 EA 200801735A1 EA 200801735 A EA200801735 A EA 200801735A EA 200801735 A EA200801735 A EA 200801735A EA 200801735 A1 EA200801735 A1 EA 200801735A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
immunogenic compositions
amyloid
multimerizing
neuritic
Prior art date
Application number
EA200801735A
Other languages
English (en)
Other versions
EA014531B1 (ru
Inventor
Симоне Оттонелло
Надя Моретто
Бруно Пьетро Имбимбо
Джино Виллетти
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Publication of EA200801735A1 publication Critical patent/EA200801735A1/ru
Publication of EA014531B1 publication Critical patent/EA014531B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем изобретении предложена рекомбинантная иммуногенная конструкция, полученная путем тандемной мультимеризации фрагмента Аβ42, несущего B-клеточный эпитоп, внутри активного петлевого участка носителя (участка дисплея), предпочтительно бактериального тиоредоксина (Trx). Полипептиды, несущие множественные копии фрагментов Аβ42, предпочтительно с расположенным между ними аминокислотным линкером, были сконструированы и инъецированы мышам в сочетании с адъювантом. Было обнаружено, что индуцированные антитела избирательно связываются с фибриллярными и/или олигомерными Аβ внутри нейритных AD-бляшек.
EA200801735A 2006-02-24 2007-02-13 Антиамилоидные иммуногенные композиции, способы и применения EA014531B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77621006P 2006-02-24 2006-02-24
PCT/EP2007/001243 WO2007096076A2 (en) 2006-02-24 2007-02-13 Anti-amyloid immunogenic compositions, methods and uses

Publications (2)

Publication Number Publication Date
EA200801735A1 true EA200801735A1 (ru) 2009-02-27
EA014531B1 EA014531B1 (ru) 2010-12-30

Family

ID=38437718

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801735A EA014531B1 (ru) 2006-02-24 2007-02-13 Антиамилоидные иммуногенные композиции, способы и применения

Country Status (13)

Country Link
US (2) US7507710B2 (ru)
EP (1) EP1996227A2 (ru)
JP (1) JP5161796B2 (ru)
KR (1) KR20080097188A (ru)
CN (1) CN101384279B (ru)
AU (1) AU2007218318A1 (ru)
BR (1) BRPI0706818A2 (ru)
CA (1) CA2638841A1 (ru)
EA (1) EA014531B1 (ru)
HK (1) HK1128614A1 (ru)
MX (1) MX2008010633A (ru)
WO (1) WO2007096076A2 (ru)
ZA (1) ZA200807228B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP1978035A1 (en) * 2007-04-05 2008-10-08 Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
EP2020240A1 (en) * 2007-07-30 2009-02-04 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Methods and substances for the treatment of Alzheimer's
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
EP2145898A1 (en) 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
DE102011057019A1 (de) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen
DE102011057021A1 (de) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
MX2016011580A (es) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albumina de suero.
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
CN109072274A (zh) * 2016-04-14 2018-12-21 道健康生活医药株式会社 淀粉样蛋白球体（aspd）样结构体及医药组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
JPH06261783A (ja) * 1993-03-16 1994-09-20 Toyota Central Res & Dev Lab Inc チオレドキシンに特異的に反応するモノクローナル抗体
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
IT1319277B1 (it) * 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
WO2005028511A2 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
HUE026000T2 (en) * 2003-12-17 2016-04-28 Wyeth Llc Immunogenic peptide-bearing conjugates and methods for their preparation
CA2584859C (en) * 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
WO2007062088A1 (en) * 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases

Also Published As

Publication number Publication date
WO2007096076A2 (en) 2007-08-30
AU2007218318A1 (en) 2007-08-30
CA2638841A1 (en) 2007-08-30
WO2007096076A3 (en) 2007-11-15
CN101384279B (zh) 2012-02-22
HK1128614A1 (en) 2009-11-06
JP5161796B2 (ja) 2013-03-13
JP2009531294A (ja) 2009-09-03
US20090186033A1 (en) 2009-07-23
EA014531B1 (ru) 2010-12-30
MX2008010633A (es) 2008-09-25
EP1996227A2 (en) 2008-12-03
CN101384279A (zh) 2009-03-11
ZA200807228B (en) 2009-11-25
BRPI0706818A2 (pt) 2011-04-05
US20070224190A1 (en) 2007-09-27
US7507710B2 (en) 2009-03-24
KR20080097188A (ko) 2008-11-04

Similar Documents

Publication Publication Date Title
EA200801735A1 (ru) Антиамилоидные иммуногенные композиции, способы и применения
MX338940B (es) Identificacion de epitopos ige novedosos.
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
EP3552622A3 (en) Priming of an immune response
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
EA201790858A2 (ru) Лечение и профилактика амилоидоза
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
AR086199A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
NZ597692A (en) Anti-IGF antibodies
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MY147217A (en) Antibody molecules having specificity for human il-06
AU2010217100A8 (en) Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
EA200700136A1 (ru) Анти-cd154-антитела
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
CR20110606A (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
GEP20125385B (en) Antibodies directed against amyloid-beta peptide and methods using same
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
UA107330C2 (ru) Туберкулезный белок rv3616c и его применение
NZ602548A (en) Oligomer-specific amyloid beta epitope and antibodies
EA201100071A1 (ru) Новые композиции и способы
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
IN2014DN07875A (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU